YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC

YAP-Dependent AXL Overexpression Mediates Resistance to EGFR Inhibitors in NSCLC

The Yes-associated protein (YAP) is a transcriptional co-activator upregulating genes that promote cell growth and inhibit apoptosis. The main dysregulation of the Hippo pathway in tumors is due to YAP overexpression, promoting epithelial to mesenchymal transition, cell transformation, and increased...

Full description

Bibliographic Details
Main Authors:	Elena Ghiso, Cristina Migliore, Vito Ciciriello, Elena Morando, Annalisa Petrelli, Simona Corso, Emmanuele De Luca, Gaia Gatti, Marco Volante, Silvia Giordano
Format:	Article
Language:	English
Published:	Elsevier 2017-12-01
Series:	Neoplasia: An International Journal for Oncology Research
Online Access:	http://www.sciencedirect.com/science/article/pii/S1476558617304001

Similar Items

Targeting AXL in NSCLC
by: Zaman A, et al.
Published: (2021-08-01)

Unexpected responses to EGFR inhibition in NSCLC
by: Giulia M. Stella, et al.
Published: (2015-01-01)

AXL receptor tyrosine kinase as a therapeutic target in NSCLC
by: Okimoto RA, et al.
Published: (2015-04-01)

Roles of YAP in EGFR-mutant lung adenocarcinoma
by: Yu-Chi Tseng, et al.
Published: (2016)

Immunohistochemical detections of EGFR status in NSCLC
by: Jie WANG, et al.
Published: (2015-04-01)

Immunohistochemical Detections of EGFR Mutations in NSCLC
by: Chang LIU, et al.
Published: (2014-09-01)

TGFβ promotes YAP‐dependent AXL induction in mesenchymal‐type lung cancer cells
by: Jeong‐Yun Choi, et al.
Published: (2021-02-01)

Combined FGFR and Akt pathway inhibition abrogates growth of FGFR1 overexpressing EGFR-TKI-resistant NSCLC cells
by: Mikkel G. Terp, et al.
Published: (2021-07-01)

EGFR-Targeted Therapeutics: Focus on SCCHN and NSCLC
by: Martin Sattler, et al.
Published: (2008-01-01)

The Impact of Variant Allele Frequency in EGFR Mutated NSCLC Patients on Targeted Therapy
by: Alex Friedlaender, et al.
Published: (2021-03-01)

THE PHARMACOGENOMICS OF EGFR-DEPENDENT NSCLC: PREDICTING AND ENHANCING RESPONSE TO TARGETED EGFR THERAPY
by: Balko, Justin M.
Published: (2009)

miR‐205 mediates adaptive resistance to MET inhibition via ERRFI1 targeting and raised EGFR signaling
by: Cristina Migliore, et al.
Published: (2018-09-01)

Expression and its Clinical Significance of NOK, EGFR in NSCLC
by: Zhipei ZHANG, et al.
Published: (2009-09-01)

Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs.
by: Chengjuan Zhang, et al.
Published: (2017-01-01)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
by: Wen M, et al.
Published: (2018-11-01)

The Receptor AXL Diversifies EGFR Signaling and Limits the Response to EGFR-Targeted Inhibitors in Triple-Negative Breast Cancer Cells
by: Meyer, Aaron Samuel, et al.
Published: (2014)

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
by: Wang Fen, et al.
Published: (2012-08-01)

Notch3-dependent β-catenin signaling mediates EGFR TKI drug persistence in EGFR mutant NSCLC
by: Rajeswara Rao Arasada, et al.
Published: (2018-08-01)

Long term follow-up of EGFR mutated NSCLC cases
by: Gad Rennert, et al.
Published: (2021-01-01)

First-line treatment of EGFR-mutant NSCLC: Spoiled for choice?
by: Ullas Batra, et al.
Published: (2019-01-01)

Review of EGFR TKIs in metastatic NSCLC, including ongoing trials
by: Barbara eMelosky
Published: (2014-09-01)

The Mechanism of Resistance to EGFR-TKI in NSCLC and Exploration to Overcome the Resistance
by: Baohui HAN, et al.
Published: (2009-12-01)

Detecting EGFR Autoantibodies in Serums of NSCLC Patients with Peptide Array
by: Yuan LI, et al.
Published: (2010-07-01)

Silibinin Inhibits NSCLC Metastasis by Targeting the EGFR/LOX Pathway
by: Xiaoying Hou, et al.
Published: (2018-02-01)

A Radiogenomics Ensemble to Predict EGFR and KRAS Mutations in NSCLC
by: Silvia Moreno, et al.
Published: (2021-04-01)

Overexpression of Wnt5a Promotes Angiogenesis in NSCLC
by: Lingli Yao, et al.
Published: (2014-01-01)

Detection of EGFR Activating and Resistance Mutations by Droplet Digital PCR in Sputum of EGFR-Mutated NSCLC Patients
by: Klaus Hackner, et al.
Published: (2021-02-01)

Pyrosequencing, a method approved to detect the two major EGFR mutations for anti EGFR therapy in NSCLC
by: Richard Marie-Jeanne, et al.
Published: (2011-05-01)

Osimertinib – effective treatment of NSCLC with activating EGFR mutations after progression on EGFR tyrosine kinase inhibitors
by: Marcin Skrzypski, et al.
Published: (2017-09-01)

Retraction notice to ‘The antineoplastic drug metformin downregulates YAP by interfering with IRF-1 binding to the YAP promoter in NSCLC’ [EBioMedicine 37 (2018) 188–204]
by: Dan Jin, et al.
Published: (2021-01-01)

Amphiregulin contained in NSCLC-exosomes induces osteoclast differentiation through the activation of EGFR pathway
by: Simona Taverna, et al.
Published: (2017-06-01)

Epidermal Growth Factor Receptor (EGFR) Pathway, Yes-Associated Protein (YAP) and the Regulation of Programmed Death-Ligand 1 (PD-L1) in Non-Small Cell Lung Cancer (NSCLC)
by: Ping-Chih Hsu, et al.
Published: (2019-08-01)

Metformin-repressed miR-381-YAP-snail axis activity disrupts NSCLC growth and metastasis
by: Dan Jin, et al.
Published: (2020-01-01)

The Crosstalk between Src and Hippo/YAP Signaling Pathways in Non-Small Cell Lung Cancer (NSCLC)
by: Ping-Chih Hsu, et al.
Published: (2020-05-01)

High Prevalence and Early Occurrence of Skeletal Complications in EGFR Mutated NSCLC Patients With Bone Metastases
by: Marta Laganà, et al.
Published: (2020-11-01)

EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies
by: Xuan Zhu, et al.
Published: (2019-10-01)

Mechanism of Xu Li’s Experiential Prescription for the Treatment of EGFR-Positive NSCLC
by: Bin Xu, et al.
Published: (2020-01-01)

Tumour Microenvironment and Immune Evasion in EGFR Addicted NSCLC: Hurdles and Possibilities
by: Antonio Santaniello, et al.
Published: (2019-09-01)

Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients
by: Jae Young Hur, et al.
Published: (2018-01-01)

Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC
by: Wu X, et al.
Published: (2013-10-01)